Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entacapone Efficacy and COMT Polymorphism in Parkinson's Disease
NCT00373087Phase 4Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2006
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Parkinson's disease (PD) comparing L-dopa + entacapone with L-dopa + placebo (2 arms). Primary endpoint: L-dopa efficacy duration on UPDRS motor scale during an acute L-dopa test at 24 hours. Started Oct 2006; status: completed.
02
Drugs
entacapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00373087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00373087.